Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TransMedics Group (TMDX)

TransMedics Q3 revenue rises 32% to $143.8 million; raises 2025 revenue outlook

Positive Impact 4 of 5 earnings Written later

TransMedics reported third quarter 2025 revenue of $143.8 million, up 32% from $108.8 million a year earlier, and net income of $24.3 million, or $0.66 per diluted share, compared with $4.2 million, or $0.12 per diluted share, in the third quarter of 2024. The company raised the midpoint of its full year 2025 revenue guidance and narrowed the range to $595 million to $605 million, which shareholders will weigh against the prior range of $585 million to $605 million.

Key points

  • Q3 2025 total revenue of $143.8 million, up 32% from $108.8 million in Q3 2024
  • Q3 2025 net income of $24.3 million, or $0.66 per diluted share, versus $4.2 million, or $0.12, a year earlier
  • Full year 2025 revenue guidance narrowed to $595 million to $605 million, from $585 million to $605 million given on July 30, 2025
  • Gross margin was 59% in Q3 2025, compared with 56% in Q3 2024; cash was $466.2 million as of September 30, 2025

The filing

CompanyTransMedics Group (TMDX)
Form8-K, current report
Filed with the SECOct 29, 2025, 4:11 PM ET
Accession number0001193125-25-256326

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.